Home › Trials › NCT05139784

Characterizing autoimmune lymphocytes in type 1 diabetes

BeAT1D: Benign Autoimmunity and Type 1 Diabetes

Observational Institut National de la Santé Et de la Recherche Médicale, France · NCT05139784

This study is trying to understand the immune cells involved in type 1 diabetes by collecting samples from people with type 1 diabetes, other types of diabetes, and healthy individuals.

Quick facts

Study typeObservational
Enrollment740 (estimated)
Ages1 Year and up
SexAll
SponsorInstitut National de la Santé Et de la Recherche Médicale, France Government
Drugs / interventionsimmunotherapy
Locations17 sites (Bobigny, Île-de-France Region and 16 other locations)
Trial IDNCT05139784 on ClinicalTrials.gov

What this trial studies

This observational study aims to collect biological samples from individuals with type 1 diabetes, other forms of diabetes, and healthy controls to analyze the characteristics of autoimmune T and B lymphocytes. By comparing these immune cells across different groups, the study seeks to clarify the mechanisms behind type 1 diabetes and identify potential biomarkers for diagnosis and treatment. The research is conducted across multiple centers in France, focusing on non-interventional biosampling.

Who should consider this trial

Good fit: Ideal candidates include individuals with type 1 diabetes, other types of diabetes, or healthy individuals without any autoimmune or metabolic disorders.

Not a fit: Patients with ongoing pregnancy or known HIV/HCV infections may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for type 1 diabetes.

How similar studies have performed: Other studies have shown promise in characterizing autoimmune responses in diabetes, suggesting that this approach may yield valuable insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Type 1 diabetes: type 1 diabetes, as defined by hyperglycemia and long-term insulin therapy started within 6 months from clinical onset; and/or the presence of at least one anti-islet auto-antibody.
2. Other forms of diabetes or autoimmune endocrinopathy: other forms of diabetes (e.g. type 2, ketosis-prone, familial, secondary, immunotherapy-induced diabetes); and/or other autoimmune endocrinopathies, isolated or multiple.
3. No diabetes: absence of diabetes or impaired glucose tolerance; absence of tumor, infectious or immune pathologies, or other conditions related to autoimmune or metabolic alterations that may bias the variables under study.
4. Lymphadenectomy planned in the frame of an abdominal surgery: pancreatic lymphadenectomy planned at the occasion of an abdominal surgery for the treatment of an underlying condition.

Exclusion Criteria:

For all participants: ongoing pregnancy; known HIV/HCV infection; absence of social security coverage; placement under judicial protection; absence of signature of the informed study consent.

Where this trial is running

Bobigny, Île-de-France Region and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Type 1 DiabetesType 1 diabetesAutoimmunityLymphocytesBeta cellsBiomarkers
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.